Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial - Concepedia

Concepedia

Publication | Open Access

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

DOI Full Paper Access

41

Citations

21

References

2017

Year

James Hakim, Cissy Kityo, Anne Hoppé, Andrew Kambugu, Joep J. van Oosterhout, Abbas Lugemwa, Abraham Siika, Raymond Mwebaze, Aggrey Mweemba, George Abongomera,

The Lancet Infectious Diseases

References

	Year	Citations

Page 1